**Former NFL Player Advocates for Awareness of Rare Heart Condition Following Personal Diagnosis**
:max_bytes(150000):strip_icc():format(jpeg)/pete-shaw-people-health-110526-1-4b9956dd5802441ebd95c524089869d6.jpg)

Pete Shaw, a 72-year-old former professional football player, is using his diagnosis of hereditary transthyretin cardiac amyloidosis (hATTR-CM) to advocate for increased awareness of the condition, particularly within the Black community. Shaw, who played as a defensive back with the San Diego Chargers and New York Giants during the 1970s and 1980s, faced years of unexplained symptoms before his diagnosis brought clarity to his struggles.

Initially, Shaw attributed his symptoms to the toll of his eight seasons in the NFL. “I thought it was just football,” he reflected on the persistent pain in his joints, the fatigue, and the shortness of breath he experienced. As he transitioned into a career as a stockbroker in San Diego, his health continued to decline. The joint pain worsened, leading to surgeries for carpal tunnel syndrome and trigger finger, whilst dizzy spells and swollen ankles began to impede his daily life.
Shaw’s breaking point came when he found himself gasping for breath on the floor of his office, fearing he was having a heart attack. Emergency room tests revealed significant abnormalities in his heart but ruled out a heart attack. It was then that he realised the severity of his situation, stating, “It was the wake-up call I couldn’t ignore. It forced me to stop brushing off the symptoms and start looking for real answers.”
Following further examination, doctors diagnosed Shaw with hATTR-CM, a rare form of cardiac amyloidosis characterised by the accumulation of transthyretin (TTR) protein deposits in the heart muscle. These deposits lead to symptoms such as fatigue and breathlessness, alongside potential complications in other organs. While Shaw has the hereditary variant of the disease, there exists a more common non-hereditary form associated with aging.
Since receiving his diagnosis, Shaw has been actively engaged in managing his health and sources of support. “Some days are better than others,” he admitted. Recognising the condition is irreversible, he remains hopeful about maintaining his quality of life. With his doctor’s approval, he has participated in charity golf events across the country and has taken on a role as an advocate for Alnylam Pharmaceuticals, aiming to educate others about the condition, especially in African American communities where awareness is notably low.
Shaw is acutely aware of the genetic implications of his diagnosis. He revealed that there is a 50% chance of passing the gene variant to each of his children. The gravity of this information was compounded by personal tragedy when he lost his youngest son, who had served in the Army, bringing an additional layer of complexity to his advocacy work. His son’s death at the age of 36 was not related to hATTR-CM, but it nonetheless motivated Shaw to share his journey and encourage others to seek testing.
“I realised you can’t do anything about the past, but you can try to make things better for the future,” Shaw stated. He believes by sharing his experiences, he can affect change and help others understand the importance of early detection, particularly among African American individuals, who statistically face a higher risk of heart disease.
Shaw’s health journey has not been an easy one. He recently underwent heart catheterisation, a procedure that prompted emotional reflection alongside his wife, Kari. This experience reminded him to honour the memory of his late son while also continuing to fight his own health battle. “Taking time to reflect and honour my son reminds me to keep fighting,” he shared, stressing that his grief fuels his advocacy.
As he rallies for awareness of hATTR-CM, Shaw emphasises that symptoms can often mimic other heart conditions, making awareness critical for early diagnosis. He encourages those experiencing a range of symptoms to consult their healthcare providers without delay. “You don’t have to tackle this alone. Build your team,” he advised, highlighting the importance of support systems in managing health challenges.
Through his advocacy, Shaw hopes to inspire others to be proactive about their health and to prioritise awareness of conditions like hATTR-CM. His journey serves as a testament to resilience and the power of community in navigating the complexities of rare diseases. As he looks to the future, Shaw remains committed to ensuring that his legacy includes a lasting impact on awareness and understanding of cardiac amyloidosis.
